益血生胶囊治疗缺铁性贫血的Meta 分析.

OBJECTIVE: To systematically review the efficacy of Yixuesheng capsules in the treatment of irondeficiency anemia (IDA), so as to provide ideas for clinical medication. METHODS: The Cochrane Library, PubMed, Embase, CNKI, Wangfang Data and VIP databases were retrieved to collect randomized controlled trials (RCT) of Yixuesheng capsules in the treatment of IDA. The retrieval time was from the establishment of the data base to Nov. 2023. The tools for literature quality and Meta-analysis were Cochrane System Evaluator Manual and RevMan 5. 4 statistical software. RESULTS: Totally 13 RCTs were enrolled, including 1 295 patients. Meta-analysis showed that compared with simply supplement of iron, the combination of Yixuesheng capsules and iron supplements can improve the total effective rate (RR =1. 23, 95%CI =1. 17-1. 29, P<0. 000 01), hemoglobin (MD = 14. 85, 95%CI = 12. 65-17. 05, P<0. 000 01), erythrocyte (MD = 0. 77, 95%CI = 0. 41-1. 14, P<0. 000 1), mean erythrocyte volume (MD =6. 07, 95%CI =1. 75-10. 39, P = 0. 006), mean corpuscular hemoglobin (MD = 3. 62, 95%CI = 3. 14-4. 11, P< 0. 000 01), serum iron (MD = 3. 95, 95%CI = 2. 51-5. 38, P<0. 000 01) and serum ferritin (MD = 16. 49, 95%CI = 9. 00-23. 97, P < 0. 000 1) after treatment, the differences were statistically significant. However, there was no significant advantage in increasing the level of transferrin receptor after treatment (MD = -5. 42, 95%CI = -13. 51- 2. 67, P =0. 19) and reducing the incidence of adverse drug reactions (RR = 0. 69, 95%CI = 0. 42-1. 12, P = 0. 14). CONCLUSIONS: The combination of Yixuesheng capsules and iron supplements has certain advantages in the treatment of IDA, yet more high-level and large-scale RCT is needed to provide data support. [ABSTRACT FROM AUTHOR]